Expanding Sales of Cyclodextrin in Food and Non-Food Applications
First written in FY2017-Q1. 12 of 30 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Revenue from the cyclodextrin segment exceeded the previous interim consolidated accounting period, partly due to large orders from certain users.」
Large orders from certain users resulted in revenue exceeding the previous interim period, reversing the lower revenue caused by product consolidation. - FY2025-H1Consolidation of products offered; lower revenueAnnual report
「Revenue from the cyclodextrin segment was below the previous year, partly due to the consolidation of products offered.」
Against a backdrop of product consolidation, revenue from the cyclodextrin segment was below the previous year. - FY2024-Q2RestatedAnnual report
「Revenue from the cyclodextrin segment exceeded the previous year because sales of products for certain users were strong.」
The company continues to benefit from revenue exceeding the previous year due to strong sales of products for certain users. - FY2024-Q1AdvancedAnnual report
「Revenue from the cyclodextrin segment exceeded the previous year because sales of products for certain users were strong.」
Strong sales of products for certain users resulted in cyclodextrin segment revenue exceeding the previous year. - FY2023RestatedAnnual report
「The cyclodextrin segment will pursue further technological improvements and other initiatives to advance the business.」
The company continues its policy of advancing the cyclodextrin business through technological improvements. - FY2022Lower revenue due to weak sales of contract-processed productsAnnual report
「Sales of contract-processed products remained sluggish, resulting in revenue below the same period of the previous year.」
The full-year results also cited weak sales of contract-processed products and lower revenue year on year. - FY2022-Q3RestatedAnnual report
「Sales of contract-processed products remained sluggish, resulting in revenue below the same quarter of the previous year.」
Weak sales of contract-processed products and the year-on-year decline in revenue have continued. - FY2022-Q2Weak sales of contract-processed productsAnnual report
「Although sales volume exceeded the previous year, revenue was below the same quarter of the previous year because sales of contract-processed products remained sluggish.」
While sales volume exceeded the previous year, weak sales of contract-processed products resulted in revenue below the same quarter of the previous year. - FY2022-Q1Lower revenue despite higher sales volume due to weak health-food salesAnnual report
「Although sales volume exceeded the previous year, revenue was below the same quarter of the previous year because sales to health-food users remained sluggish.」
While sales volume exceeded the previous year, weak sales to health-food users resulted in revenue below the same quarter of the previous year. - FY2021The full-year impact of weak sales caused by the COVID-19 pandemicAnnual report
「Sales to the foodservice and souvenir industries were affected by the COVID-19 pandemic, while usage also declined due to recipe changes in end-user products and other factors. Overall sales remained sluggish, and revenue was below the same period of the previous year.」
Weakness in foodservice and souvenir sales, together with lower usage of end products, resulted in revenue below the same period of the previous year for the full year as well. - FY2021-Q3Weak foodservice sales and lower usage despite stay-at-home demandAnnual report
「Some products performed well as stay-at-home demand increased, but the foodservice industry was severely affected by the COVID-19 pandemic, resulting in difficult overall sales conditions for cyclodextrin. In addition, usage declined due to changes in end-user products and recipes, and revenue was below the same quarter of the previous year.」
While some products performed well on stay-at-home demand, the segment as a whole recorded lower revenue due to the impact on the foodservice industry and lower usage resulting from discontinued end-user products, recipe changes and other factors. - FY2021-Q2Discontinued products and recipe changes despite strong sales to health-food customers; weak foodservice salesAnnual report
「Sales to companies related to health foods remained strong, but usage declined due to product discontinuations and recipe changes by end-user customers. Sales to foodservice users also remained sluggish, resulting in revenue below the same quarter of the previous year.」
While sales to health-food-related companies were strong, lower usage due to product discontinuations and recipe changes by end-user customers, together with weak foodservice sales, resulted in revenue below the same quarter of the previous year. - FY2021-Q1Weak sales to major users and foodservice usersAnnual report
「Sales to major users were weak, and sales to foodservice users affected by COVID-19 also remained sluggish. As a result, revenue was below the same quarter of the previous year.」
Sales to major users and foodservice users affected by COVID-19 were sluggish, and revenue was below the same quarter of the previous year. - FY2020AdvancedAnnual report
「The cyclodextrin segment pursued the development of new applications and the strengthening of sales capabilities. As a result, sales to major users of key products and processed products remained solid, and the segment as a whole recorded lower revenue but higher profit.」
The company continued developing new applications and strengthening sales capabilities, while sales to major users of key products and processed products remained solid. - FY2020-Q3AdvancedAnnual report
「Sales to major users of key products and processed products remained strong, resulting in higher revenue and profit for the cyclodextrin segment as a whole.」
Sales to major users of key products and processed products remained strong, resulting in higher revenue and profit for the segment as a whole. - FY2020-Q2Expansion into processed products and contract processingAnnual report
「The cyclodextrin segment actively expanded sales of processed products using cyclodextrin and manufactured products on a contract-processing basis at customers' request. As a result, the segment as a whole recorded lower revenue but higher profit.」
In addition to expanding sales to food and non-food applications, the company cited sales of processed products and contract processing at customers' request as measures. - FY2020-Q1RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and stronger sales capabilities for food and non-food products. As a result, sales volume was below the previous year, while revenue exceeded the previous year.」
The company continued expanding sales to food and non-food applications through new-application development and stronger sales capabilities. Sales volume declined, while revenue increased. - FY2019RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food products, but revenue was below the same period of the previous year.」
While continuing its policy of expanding sales to food and non-food applications, full-year revenue was below the same period of the previous year. - FY2019-Q3RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food products, but revenue was below the previous year.」
While continuing to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food applications, revenue was below the previous year. - FY2019-Q2Continued development of new applications and materials; lower revenueAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food products, but revenue was below the previous year.」
While continuing to develop new applications and materials and strengthen sales capabilities, revenue was below the previous year. - FY2019-Q1New applications and stronger sales capabilities; lower volume and higher revenueAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and stronger sales capabilities for food and non-food products. As a result, sales volume was below the previous year, while revenue exceeded the previous year.」
The company continued expanding sales to food and non-food applications, citing new-application development and stronger sales capabilities as specific measures. Sales volume declined, while revenue increased. - FY2018-Q3RestatedAnnual report
「The cyclodextrin business worked to expand sales to both food and non-food applications, but revenue was below the same period of the previous year.」
While continuing its policy of expanding sales to both food and non-food applications, revenue was below the same period of the previous year. - FY2018-Q2RestatedAnnual report
「As a result of efforts to expand sales to both food and non-food applications, revenue from the cyclodextrin business was approximately in line with the previous year.」
The company continues its policy of expanding sales to both food and non-food applications. - FY2018-Q1RestatedAnnual report
「As a result of efforts to expand sales to both food and non-food applications, revenue from the cyclodextrin business was approximately in line with the previous year.」
The company continues its policy of expanding sales to both food and non-food applications. - FY2017-Q3RestatedAnnual report
「The cyclodextrin business worked to expand sales to both food and non-food applications, but revenue was below the same period of the previous year.」
While continuing its policy of expanding sales to both food and non-food applications, revenue was below the same period of the previous year. - FY2017-Q2RestatedAnnual report
「The cyclodextrin business worked to expand sales in food and non-food applications, but net sales were broadly level with the previous year.」
The company continues to pursue sales expansion in both food and non-food applications, while net sales remain broadly level with the previous year. - FY2017-Q1First statedAnnual report
「The cyclodextrin business worked to expand sales in food and non-food applications, but net sales were broadly level with the previous year.」
The company is pursuing sales expansion in both food and non-food applications.